MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

18.31 -2.66

Buy Sell

Overview

Share price change

24h

Current

Min

18.07

Max

18.81

Key metrics
By Trading Economics
Income	4.8M -36M
Sales	6.1M 116M
Profit margin	-30.977
Employees	1,869
EBITDA	24M -31M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+125.8% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	-955M 2.1B
Previous open	20.97
Previous close	18.31

News Sentiment

By Acuity

50%

177 / 360 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 sty 2026, 23:49 UTC

Major Market Movers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 sty 2026, 21:12 UTC

Major Market Movers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 sty 2026, 20:29 UTC

Major Market Movers

Chip Makers Gain After Trump Calls Off European Tariffs

21 sty 2026, 20:04 UTC

Major Market Movers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 sty 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 sty 2026, 22:39 UTC

Earnings

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 sty 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 sty 2026, 21:19 UTC

Earnings

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 sty 2026, 20:45 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 sty 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 sty 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 sty 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 sty 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 sty 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 sty 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 sty 2026, 20:23 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 sty 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 sty 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 sty 2026, 20:08 UTC

Earnings

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 sty 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 sty 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 sty 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 sty 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 sty 2026, 19:24 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 sty 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 sty 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

125.8% upside

12 Months Forecast

Average 42.54 USD 125.8%

High 58 USD

Low 25.7 USD

Based on 5 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

177 / 360 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.